Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.51 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.44 |
| ▸ | LTA4H | P09960 | 4/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17801791 | 1.00 | SPHK1 (0.51) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL18867987 | 0.90 | SPHK1 (0.49) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL19234501 | 0.88 | SPHK1 (0.53) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL17448175 | 0.88 | LTA4H (0.52) | SPHK1SPHK2LTA4H | |
| SCHEMBL31063980 | 0.87 | SPHK1 (0.40) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL19132239 | 0.86 | HDAC2 (0.41) | SPHK1SPHK2 | |
| SCHEMBL16847450 | 0.86 | SPHK1 (0.53) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL20715717 | 0.86 | TRPV1 (0.49) | SPHK1SPHK2S1PR1S1PR3S1PR4 | |
| SCHEMBL18099876 | 0.85 | HSD17B10 (0.49) | SPHK1SPHK2 | |
| SCHEMBL6287037 | 0.85 | SPHK1 (0.43) | SPHK1SPHK2S1PR1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684399-A | Synthesis method of Val-Cit dipeptide linker | 浙江工业大学 | 2025-03-25 | — | — | CN | claimed |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | GENMAB AS (DK) | 2026-03-26 | — | — | US | disclosed |
| EP-3725798-B1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| EP-4667495-A2 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| EP-4637833-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | Genentech, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12454527-B2 | Conjugate monomethyl auristatin E to obtain a composition for treatment of prostate cancer | IZVARINO FARMA AB (SE) | 2025-10-28 | — | — | US | disclosed |
| EP-4608451-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | Genmab A/S (DK) | 2025-09-03 | — | — | EP | disclosed |
| EP-4600271-A2 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-13 | — | — | EP | disclosed |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2016090040-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090050-A1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090038-A1 | ANTI-STAPHYLOCOCCUS AUREUS ANTIBODY RIFAMYCIN CONJUGATES AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016008392-A1 | LINKERS AND THEIR APPLICATION TOWARDS ADC | MEDSHINE DISCOVERY INC. (CN) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016008112-A1 | LINKERS AND APPLICATION TOWARDS ADC THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2016-01-21 | — | — | WO | disclosed |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| WO-2015095223-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095124-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095227-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20110160147-A1 | NOVEL DUAL TARGETING ANTITUMORAL CONJUGATES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160147-A1 | NOVEL DUAL TARGETING ANTITUMORAL CONJUGATES | PAICS, SI, MPI | SPHK1 2490/4885SPHK2 2864/4885S1PR1 1746/4885 |
| US-20250213685-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | SPHK1 4443/4885SPHK2 3946/4885S1PR1 3434/4885 |
| US-12454527-B2 | Conjugate monomethyl auristatin E to obtain a composition for treatment of prostate cancer | FOLH1, AURKA, MAN2B2 | SPHK1 1650/4885SPHK2 2192/4885S1PR1 1392/4885 |
| US-20260083853-A1 | CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME | CD74, HACD3, FCGR2A | SPHK1 4778/4885SPHK2 4642/4885S1PR1 3185/4885 |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | PBRM1, BRWD1, BRDT | SPHK1 4301/4885SPHK2 4228/4885S1PR1 3683/4885 |
| US-20250177374-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | SPHK1 2953/4885SPHK2 2693/4885S1PR1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.